Systemic administration of a therapeutic preparation
원문보기
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
A61K-03828
C07K-01462
출원번호
US-0158554
(1998-09-22)
우선권정보
SE-0000372 (1994-02-04); SE-0002198 (1993-06-24)
발명자
/ 주소
B?ckstr?m, Kjell G?ran Erik
Dahlb?ck, Carl Magnus Olof
Edman, Peter
Johansson, Ann Charlotte Birgit
출원인 / 주소
AstraZeneca AB
대리인 / 주소
Fish &
인용정보
피인용 횟수 :
2인용 특허 :
68
초록▼
A method of treating a patient in need of insulin treatment, including the steps of introducing into the lower respiratory tract of the patient an effective amount of a therapeutic preparation in the form of a dry powder containing (a) insulin and (b) an enhancer compound which enhances the absorpti
A method of treating a patient in need of insulin treatment, including the steps of introducing into the lower respiratory tract of the patient an effective amount of a therapeutic preparation in the form of a dry powder containing (a) insulin and (b) an enhancer compound which enhances the absorption of insulin in the lungs of the patient.
대표청구항▼
1. A method of treating a patient in need of insulin treatment, comprising introducing through the mouth and into the lower respiratory tract of said patient an effective amount of a dry powder composition, the active ingredients of which consist of (a) insulin and (b) one or more enhancers which en
1. A method of treating a patient in need of insulin treatment, comprising introducing through the mouth and into the lower respiratory tract of said patient an effective amount of a dry powder composition, the active ingredients of which consist of (a) insulin and (b) one or more enhancers which enhance the absorption of insulin in the lower respiratory tract of said patient, each of the one or more enhancers being selected from the group consisting of a bile salt, a C8-C16 fatty acid, a salt of a C8-C16 fatty acid, an acyl carnitine, a salt of glycyrrhizine, a phospholipid, a cyclodextrin, and an alkyl saccharide, wherein the dry powder composition is introduced into the lower respiratory tract of the patient by inhalation from a dry powder inhaler device, provided that, if any of the one or more enhancers is a double-chain phospholipid, each chain of the double-chain phospholipid is eight or fewer carbon atoms in length.2. The method of claim 1, wherein at least 50% of the total mass of said active ingredients in said dry powder composition, at the point of introduction into the respiratory system of said patient, consists of particles having a diameter of about 10 microns or less.3. The method of claim 2, wherein said dry powder composition is supplied as agglomerates of said particles of said active ingredients contained in an inhaler device, said agglomerates being substantially deagglomerated prior to entry into the respiratory system of said patient.4. The method of claim 3, wherein the dry powder composition is supplied as an ordered mixture of particles of active ingredients having a diameter of about 10 microns or less and particles of a carrier substance additionally comprised in said dry powder composition, contained in an inhaler device.5. The method of claim 3, wherein said particles are inhaled by said patient from said inhaler device, said agglomerates being substantially deagglomerated by air turbulence in said inhaler device.6. The method of claim 2, wherein said patient inhales said dry powder composition from a single-dose, dry powder inhaler device.7. The method of claim 1, wherein said insulin is human insulin.8. The method of claim 1, wherein said one or more enhancers includes a trihydroxy bile salt.9. The method of claim 1, wherein said one or more enhancers includes a salt of cholic, glycocholic, or taurocholic acid.10. The method of claim 1, wherein said one or more enhancers includes a sodium or potassium salt of cholic acid.11. The method of claim 1, wherein said one or more enhancers includes a sodium or potassium salt of glycocholic acid.12. The method of claim 1, wherein said one or more enhancers includes sodium taurocholate.13. The method of claim 1, wherein said one or more enhancers includes potassium taurocholate.14. The method of claim 1, wherein said one or more enhancers includes a salt of chenodeoxycholic acid, glycochenodeoxycholic acid, taurochenodeoxycholic acid, deoxycholic acid, glycodeoxycholic acid, taurodeoxycholic acid, lithocholic acid, or ursodeoxycholic acid.15. The method of claim 1, wherein the ratio of (a) to (b) in said dry powder composition is between about 9:1 and about 1:1.16. The method of claim 1, wherein at least 50% of the total mass of said active ingredients is in the form of particles which have a diameter of 10 microns or less, or of agglomerates of said particles.17. A method of treating a patient in need of insulin treatment, comprising introducing into the lower respiratory tract of the patient, from a dry powder inhaler device, a dry powder pharmaceutical preparation, the active ingredients of which consist of (a) insulin and (b) one or more enhancers which enhance the systemic absorption of insulin in the lower respiratory tract of said patient, each of the one or more enhancers being selected from the group consisting of a bile salt, a C8-C16 fatty acid, a salt of a C8-C16 fatty acid, an acyl carnitine, a salt of qlycyrrhizine, a phospholipid, a cyclodextrin, and an alkyl saccharide, provided that, at the point the preparation enters the respiratory tract of the patient, at least 50% of the total mass of active ingredients consists of particles having a diameter of about 10 microns or less, wherein the plasma pharmacokinetics of said insulin delivered by said method more closely resemble the plasma pharmacokinetics of endogenous insulin secreted by a healthy individual in response to a glucose challenge, than do the plasma pharmacokinetics of human insulin delivered by subcutaneous injection.18. The method of claim 17, wherein said one or more enhancers includes a trihydroxy bile salt.19. The method of claim 17, wherein said one or more enhancers includes a salt of cholic, glycocholic, or taurocholic acid.20. The method of claim 17, wherein said one or more enhancers includes a sodium or potassium salt of cholic acid.21. The method of claim 17, wherein said one or more enhancers includes a sodium or potassium salt of glycocholic acid.22. The method of claim 17, wherein said one or more enhancers includes sodium taurocholate.23. The method of claim 17, wherein said one or more enhancers includes potassium taurocholate.24. The method of claim 17, wherein said one or more enhancers includes a salt of chenodeoxycholic acid, glycochenodeoxycholic acid, taurochenodeoxycholic acid, deoxycholic acid, glycodeoxycholic acid, taurodeoxycholic acid, lithocholic acid, or ursodeoxycholic acid.25. The method of claim 17, wherein the ratio of (a) to (b) in said dry powder pharmaceutical preparation is between about 9:1 and about 1:1.26. The method of claim 17, wherein said patient inhales said dry powder pharmaceutical preparation from a single-dose, dry powder inhaler device.27. The method of claim 1, wherein the dry powder composition contains only said active ingredients.28. The method of claim 1, wherein the dry powder composition contains, in addition to said active ingredients, a pharmaceutically acceptable carrier.29. The method of claim 1, wherein said one or more enhancers includes a sodium, potassium or lysine salt of caprylic acid (C8), capric acid (C10), lauric acid (C12), or myristic acid (C14).30. The method of claim 1, wherein said one or more enhancers includes a single- or double-chain phospholipid.31. The method of claim 1, wherein said one or more enhancers includes at least one phospholipid selected from the group consisting of lysophosphatidylcholine, lysophosphatidylglycerol, lysophosphatidylethanolamine, lysophosphatidylinositol, lysophosphatidylserine, diacylphosphatidylcholine, diacylphosphatidylglycerol, diacylphosphatidylethanolamine, diacylphosphatidylinositol, and diacylphosphatidylserine.32. The method of claim 1, wherein said one or more enhancers includes palmitoylphosphatidylglycerol, palmitoylphosphatidylcholine, dioctanoylphosphatidyl-glycerol or dioctanoylphosphatidylcholine.33. The method of claim 1, wherein said one or more enhancers includes an alkyl glucoside or alkyl maltoside.34. The method of claim 1, wherein said one or more enhancers includes decyl glucoside, dodecyl glucoside, decyl maltoside, or dodecyl maltoside.35. The method of claim 1, wherein said one or more enhancers includes a sodium or potassium salt of glycyrrhizine.36. The method of claim 1, wherein said one or more enhancers includes decanoyl carnitine, lauryl carnitine, myristoyl carnitine, or palmitoyl carnitine.37. The method of claim 1, in which at least 50% of the dry powder composition consists of (a) particles having a diameter of between 1 and 6 microns or (b) agglomerates of such particles.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (68)
Meezan Elias (Birmingham AL) Pillion Dennis J. (Birmingham AL), Absorption enhancers for drug administration.
Alexander Jose (Lawrence KS) Fix Joseph A. (Lawrence KS) Repta A. J. (Lawrence KS), Acylcarnitines as absorption-enhancing agents for drug delivery through mucous membranes of the nasal, buccal, sublingua.
Alexander Jose (Lawrence KS) Repta A. J. (Lawrence KS) Fix Joseph A. (Lawrence KS), Acylcarnitines as absorption-enhancing agents for drug delivery through mucous membranes of the nasal, buccal, sublingua.
Wang Yu-chang J. (Los Altos CA) Lee William A. (Los Altos CA) Narog Blair (Palo Alto CA), Composition and method for administration of pharmaceutically active substances.
Stanley Theodore H. (Salt Lake City UT) Hague Brian (West Valley City UT), Compositions of oral nondissolvable matrixes for transmucosal administration of medicaments.
Newhouse Michael T. (436 Queen Street South Hamilton ; Ontario CAX L8N 4A6) Baines W. Douglas (1675 Wedmore Way Mississauga ; Ontario CAX), Dry powder inhaler and process that explosively discharges a dose of powder and gas from a soft plastic pillow.
Radhakrishnan Ramachandran (Fremont CA) Mihalko Paul J. (Fremont CA) Abra Robert M. (San Francisco CA), Method and apparatus for administering dehydrated liposomes by inhalation.
Hora Maninder Singh ; Rubinfeld Joseph ; Stern Warren ; Wong Gregory J., Method and compositions for solubilization and stabilization of polypeptides, especially proteins.
Greenleaf David J. (Loughborough GB3) Purewal Tarlochan S. (Leamington Spa GB3) Jinks Philip A. (Mount Sorrel GB3), Method for preparing medicinal aerosol formulation containing coated medicament.
Weiner Howard L. ; Eisenberth George ; Hafler David Allen ; Zhang Zhengi, Method of treating or preventing type 1 diabetes by oral administration of insulin.
Fassberg Julianne (New York NY) Sequeira Joel A. (New York NY) Chaudry Imtiaz A. (North Caldwell NJ) Kopcha Michael (East Brunswick NJ), Non-chlorofluorocarbon aerosol formulations.
Boyes Robert N. (St. Albans AL GB2) Tice Thomas R. (Birmingham AL) Gilley Richard M. (Birmingham AL) Pledger Kenneth L. (Huntsville AL), Pharmaceutical formulations comprising microcapsules.
Backstrom Kjell Goran Erik,SEX ; Dahlback Carl Magnus Olof,SEX ; Edman Peter,SEX ; Johansson Ann Charlotte Birgit,SEX, Processes for preparing compositions for inhalation.
Platz Robert M. (Half Moon Bay CA) Winters Mark A. (Mountain View CA) Pitt Colin G. (Thousand Oaks CA), Pulmonary administration of granulocyte colony stimulating factor.
Benson Bradley J. (170 Cresta Vista Dr. San Francisco CA 94127) Wright JoRae (170 Cresta Vista Dr. San Francisco CA 94127), Pulmonary administration of pharmaceutically active substances.
Backstrom Kjell Goran Erik,SEX ; Dahlback Carl Magnus Olof,SEX ; Edman Peter,SEX ; Johansson Ann Charlotte Birgit,SEX, Systemic administration of a therapeutic preparation.
Bckstrm Kjell G. E. (Lund SEX) Dahlbck Carl M. O. (Lund SEX) Edman Peter (Bjrred SEX) Johansson Ann C. B. (Lund SEX), Systemic administration of a therapeutic preparation.
Backstrom Kjell Goran Erik (Lund SEX) Dahlback Carl Magnus Olof (Lund SEX) Edman Peter (Bjarred SEX) Johansson Ann Charlotte Birgit (Lund SEX), Therapeutic preparation for inhalation.
Backstrom Kjell Goran Erik,SEX ; Dahlback Carl Magnus Olof,SEX ; Edman Peter,SEX ; Johansson Ann Charlotte Birgit,SEX, Therapeutic preparation for inhalation.
Backstrom Kjell Goran Erik,SEX ; Dahlback Carl Magnus Olof,SEX ; Edman Peter,SEX ; Johansson Ann Charlotte Birgit,SEX, Therapeutic preparation for inhalation.
Backstrom Kjell Goran Erik,SEX ; Dahlback Carl Magnus Olof,SEX ; Edman Peter,SEX ; Johansson Ann Charlotte Birgit,SEX, Therapeutic preparation for inhalation.
Bckstrm Kjell G. E. (Lund SEX) Dahlbck Carl M. O. (Lund SEX) Edman Peter (Bjrred SEX) Johansson Ann C. B. (Lund SEX), Therapeutic preparation for inhalation.
Longenecker John P. (Mountain View CA) Ennis Richard (Fremont CA) Baldwin Patricia A. (Hayward CA) Lee William A. (Los Altos CA), Transmembrane formulations for drug administration.
Schultz Robert K. (Shoreview MN) Quessy Stephen N. (St. Paul MN), Use of soluble fluorosurfactants for the preparation of metered-dose aerosol formulations.
Leigh, Steve; Leigh, Mathew Louis Steven; Van Hoogevest, Peter; Streich, Daniel; Quinton, Jacques, Dissolution composition for examining drug solubility.
Leigh, Steve; Leigh, Matthew Louis Steven; Van Hoogevest, Peter; Streich, Daniel; Quinton, Jacques, Dissolution composition for examining drug solubility.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.